Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Stepanova

Showing results (101-110 of 242) with videos related to

Pageof 25
Sort By:
Obesity Surgery|February 2, 2010
Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver diseaseMaria Stepanova, Noreen Hossain, Arian Afendy, et al.
Hepatology Communications|February 7, 2018
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver diseaseZobair M Younossi, Maria Stepanova, Nila Rafiq, et al.
Journal of Clinical and Experimental Hepatology|April 9, 2026
Self-Reported Cognitive Function in Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom TrialsZobair M Younossi, Fatema Nader, Dominic Labriola, et al.
Hepatology (Baltimore, Md.)|July 18, 2018
Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource UseMehmet Sayiner, Pegah Golabi, Maria Stepanova, et al.
Alimentary Pharmacology & Therapeutics|November 12, 2022
Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based studyYusuf Yilmaz, Ahmet Eren Toraman, Ceyda Alp, et al.
Annals of Hepatology|February 10, 2025
Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)Zobair M Younossi, James M Paik, Linda Henry, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 29, 2011
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008Zobair M Younossi, Maria Stepanova, Mariam Afendy, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 11, 2015
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS studyZobair M Younossi, Maria Stepanova, Stanislas Pol, et al.
Hepatology (Baltimore, Md.)|March 2, 2011
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortalityZobair M Younossi, Maria Stepanova, Nila Rafiq, et al.
Frontiers in Immunology|April 18, 2022
Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical FindingsEkaterina Kushnareva, Maria Stepanova, Elizaveta Artemeva, et al.
Pageof 25

Showing results (101-110 of 242) with videos related to

Sort By:
Pageof 25
Obesity Surgery|February 2, 2010
Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver diseaseMaria Stepanova, Noreen Hossain, Arian Afendy, et al.
Hepatology Communications|February 7, 2018
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver diseaseZobair M Younossi, Maria Stepanova, Nila Rafiq, et al.
Journal of Clinical and Experimental Hepatology|April 9, 2026
Self-Reported Cognitive Function in Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom TrialsZobair M Younossi, Fatema Nader, Dominic Labriola, et al.
Hepatology (Baltimore, Md.)|July 18, 2018
Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource UseMehmet Sayiner, Pegah Golabi, Maria Stepanova, et al.
Alimentary Pharmacology & Therapeutics|November 12, 2022
Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based studyYusuf Yilmaz, Ahmet Eren Toraman, Ceyda Alp, et al.
Annals of Hepatology|February 10, 2025
Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)Zobair M Younossi, James M Paik, Linda Henry, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 29, 2011
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008Zobair M Younossi, Maria Stepanova, Mariam Afendy, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 11, 2015
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS studyZobair M Younossi, Maria Stepanova, Stanislas Pol, et al.
Hepatology (Baltimore, Md.)|March 2, 2011
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortalityZobair M Younossi, Maria Stepanova, Nila Rafiq, et al.
Frontiers in Immunology|April 18, 2022
Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical FindingsEkaterina Kushnareva, Maria Stepanova, Elizaveta Artemeva, et al.
Pageof 25